Ischemic Heart Disease Clinical Trial
— rEPIC07Official title:
Coroflex® ISAR NEO Coronary Stent System Post-Market Clinical Follow-up Study
International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Coroflex® ISAR NEO coronary stent system sirolimus eluting stent.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | February 1, 2027 |
Est. primary completion date | February 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Coroflex® ISAR NEO is intended to be used for - Patients must be at least 18 years of age AND - The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND - Patients with Novo lesion length 2-4 mm AND - Informed consent signed Exclusion Criteria: - Patients with express refusal by the patient to participate in the study. - Patients pregnant women and lactating women. - Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4). - Patients with contraindications or hypersensitivity to sirolimus. - Patients with a life expectancy of less than 2 years. - Patients included in other clinical trials. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Badajoz | Badajoz | |
Spain | Hospital Universitari Germans Trias I Pujol | Badalona | |
Spain | Hospital Universitario de Cruces | Barakaldo | |
Spain | Hospital Universitari Vall D Hebron | Barcelona | |
Spain | Hospital Universitario San Pedro de Alcantara | Cáceres | |
Spain | Hospital General Universitario de Ciudad Real | Ciudad Real | |
Spain | Hospital Universitario A Coruña | Coruña | |
Spain | Hospital Universitario Juan Ramon Jimenez | Huelva | |
Spain | Hospital Universitario de Leon | León | |
Spain | Hospital Universitario Lucus Agusti | Lugo | |
Spain | Hospital Clinico Universitario Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Fundación EPIC |
Spain,
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. No abstract available. Erratum In: Eur Heart J. 2020 Nov 21;41(44):4242. — View Citation
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. Erratum In: Eur Heart J. 2019 Oct 1;40(37):3096. — View Citation
Ruiz-Nodar JM, Ferreiro JL. Tratamiento antitrómbotico tras revascularización percutánea en pacientes con indicación crónica de anticoagulación oral. REC Interv Cardiol. 2019;1(1):41-50.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Endpoint. Freedom from Target Lesion Failure | Freedom from TARGET LESION FAILURE (TLF), composite endpoint of Cardiac death, Myocardial infarction, stent thrombosis (Academic Research Consortium definitive/ probable), and new Target Lesion Revascularization (TLR) | 7 days | |
Primary | Efficacy Endpoint. Freedom fromTarget Lesion Failure | Freedom from TARGET LESION FAILURE (TLF), composite endpoint of Cardiac death, Myocardial infarction, and new Target Lesion Revascularization (TLR). | 7 days | |
Secondary | Freedom from Accidental dislodgement of the stent | Freedom from Accidental dislodgement of the stent | During percutaneous coronary intervention (PCI) | |
Secondary | Freedom from Balloon rupture | Freedom from Balloon rupture | During PCI | |
Secondary | Freedom from Hypotube rupture | Freedom from Hypotube rupture | During PCI | |
Secondary | Freedom from Complicated withdrawal | Freedom from Complicated withdrawal | During PCI | |
Secondary | Freedom from Coronary perforation | Freedom from Coronary perforation | During PCI | |
Secondary | Freedom from Coronary dissection >C | Freedom from Coronary dissection >C | During PCI | |
Secondary | Freedom from No reflow | Freedom from No reflow | During PCI | |
Secondary | Freedom from Coronary thrombosis | Freedom from Coronary thrombosis | During PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |